Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?
作者信息
Klement Giannoula Lakka, Kamen Barton A
出版信息
J Pediatr Hematol Oncol. 2011 Jan;33(1):1-3. doi: 10.1097/MPH.0b013e3182024918.
Abstract
摘要
相似文献
1
Nontoxic, fiscally responsible, future of oncology: could it be beginning in the Third World?无毒、对财政负责、肿瘤学的未来：会始于第三世界吗？
J Pediatr Hematol Oncol. 2011 Jan;33(1):1-3. doi: 10.1097/MPH.0b013e3182024918.
2
Concomitant medications in cancer patients: should we be more active in their management?癌症患者的合并用药：我们在其管理中是否应更加积极？
Ann Oncol. 2010 Feb;21(2):430. doi: 10.1093/annonc/mdp539. Epub 2009 Nov 25.
3
Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer.引言：耐药性乳腺癌患者化疗的当前及未来方法
Semin Oncol. 2011 Jun;38 Suppl 2:S1-2. doi: 10.1053/j.seminoncol.2011.04.001.
4
Targeting the human kinome for cancer therapy.以人类激酶组为靶点进行癌症治疗。
Crit Rev Oncog. 2012;17(1):vi-vii. doi: 10.1615/critrevoncog.v17.i1.10.
5
Discrete event simulation applied to pediatric phase I oncology designs.离散事件模拟应用于儿科一期肿瘤学设计。
Clin Pharmacol Ther. 2008 Dec;84(6):729-33. doi: 10.1038/clpt.2008.193. Epub 2008 Oct 15.
6
What are the expected developments in the medical treatment of bladder cancer.
Eur J Cancer. 2011 Sep;47 Suppl 3:S294-7. doi: 10.1016/S0959-8049(11)70177-0.
7
Combination therapies in oncology.肿瘤学中的联合疗法。
Nat Rev Drug Discov. 2016 Feb;15(2):81-2. doi: 10.1038/nrd.2016.3.
8
[Second-line treatment of metastatic non-small cell lung carcinoma: What are the options today? What are the perspectives for tomorrow?].[转移性非小细胞肺癌的二线治疗：当今有哪些选择？未来有哪些前景？]
Rev Mal Respir. 2012 Jan;29(1):4-6. doi: 10.1016/j.rmr.2011.12.006.
9
Practical designs for Phase I combination studies in oncology.肿瘤学中I期联合研究的实用设计。
J Biopharm Stat. 2016;26(1):150-66. doi: 10.1080/10543406.2015.1092029.
10
[Cancer chemotherapy in the future. Discussion].
Gan To Kagaku Ryoho. 2003 Oct;30(10):1422-33.
引用本文的文献
1
Metronomic chemotherapy in cancer treatment: new wine in an old bottle.节拍化疗在癌症治疗中的应用：陈酒新瓶。
Theranostics. 2024 Jun 1;14(9):3548-3564. doi: 10.7150/thno.95619. eCollection 2024.
2
Metronomics: Intrinsic Anakoinosis Modulator?节拍化疗：内在适应性调节剂？
Front Pharmacol. 2018 Jun 25;9:689. doi: 10.3389/fphar.2018.00689. eCollection 2018.
3
An in vitro assessment of liposomal topotecan simulating metronomic chemotherapy in combination with radiation in tumor-endothelial spheroids.脂质体拓扑替康模拟节拍化疗联合放疗在肿瘤内皮球体中的体外评估
Sci Rep. 2015 Oct 15;5:15236. doi: 10.1038/srep15236.
4
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.节拍化疗：一种有吸引力的替代最大耐受剂量疗法的方法，它可以激活抗肿瘤免疫并使治疗耐药性最小化。
Cancer Lett. 2015 Mar 28;358(2):100-106. doi: 10.1016/j.canlet.2014.12.039. Epub 2014 Dec 23.
5
Metronomics: towards personalized chemotherapy?节拍化疗：迈向个体化化疗？
Nat Rev Clin Oncol. 2014 Jul;11(7):413-31. doi: 10.1038/nrclinonc.2014.89. Epub 2014 Jun 10.
6
Generalized principles of stochasticity can be used to control dynamic heterogeneity.可以利用随机性的普遍原理来控制动态异质性。
Phys Biol. 2012 Dec;9(6):065006. doi: 10.1088/1478-3975/9/6/065006. Epub 2012 Nov 29.
7
Conceptualizing a tool to optimize therapy based on dynamic heterogeneity.基于动态异质性概念化优化治疗的工具。
Phys Biol. 2012 Dec;9(6):065005. doi: 10.1088/1478-3975/9/6/065005. Epub 2012 Nov 29.
8
Pilot study of a pediatric metronomic 4-drug regimen.儿童节拍器4药方案的初步研究。
Oncotarget. 2011 Dec;2(12):960-5. doi: 10.18632/oncotarget.358.
9
Moving forward with metronomic chemotherapy: meeting report of the 2nd International Workshop on Metronomic and Anti-Angiogenic Chemotherapy in Paediatric Oncology.推进节拍化疗：第二届儿科肿瘤学节拍化疗和抗血管生成化疗国际研讨会会议报告。
Transl Oncol. 2011 Aug;4(4):203-11. doi: 10.1593/tlo.11124. Epub 2011 Aug 1.
本文引用的文献
1
Children treated with metronomic chemotherapy in a low-income country: METRO-MALI-01.在低收入国家接受节拍化疗的儿童：METRO - MALI - 01。
J Pediatr Hematol Oncol. 2011 Jan;33(1):31-4. doi: 10.1097/MPH.0b013e3182018ab8.
2
Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.潜在的钟形和 U 形剂量反应与癌症中血管生成的治疗靶向相关。
Dose Response. 2010 Apr 23;8(3):253-84. doi: 10.2203/dose-response.09-049.Reynolds.
3
A phase II study of high-dose celecoxib and metronomic 'low-dose' cyclophosphamide and methotrexate in patients with relapsed and refractory lymphoma.一项关于高剂量塞来昔布与节拍性“低剂量”环磷酰胺及甲氨蝶呤用于复发难治性淋巴瘤患者的II期研究。
Hematol Oncol Stem Cell Ther. 2010;3(1):13-8. doi: 10.1016/s1658-3876(10)50051-7.
4
Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.每日达肝素和环磷酰胺、每周两次甲氨蝶呤、每日泼尼松的节拍化疗联合治疗转移性乳腺癌的 I/II 期试验，以血管内皮生长因子和可溶性血管内皮生长因子受体水平作为反应标志物。
J Clin Oncol. 2010 Feb 10;28(5):723-30. doi: 10.1200/JCO.2009.24.0143. Epub 2009 Dec 21.
5
Tumour dormancy in breast cancer: an update.乳腺癌中的肿瘤休眠：最新进展
Breast Cancer Res. 2007;9(3):208. doi: 10.1186/bcr1677.
6
In vivo inhibition of human hepatocellular carcinoma related angiogenesis by vinblastine and rapamycin.长春碱和雷帕霉素对人肝细胞癌相关血管生成的体内抑制作用
Histol Histopathol. 2007 Mar;22(3):285-9. doi: 10.14670/HH-22.285.
7
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer.曲妥珠单抗联合小剂量环磷酰胺和甲氨蝶呤治疗HER-2阳性转移性乳腺癌患者。
BMC Cancer. 2006 Sep 15;6:225. doi: 10.1186/1471-2407-6-225.
8
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.小剂量环磷酰胺方案可选择性清除终末期癌症患者的CD4+CD25+调节性T细胞，并恢复T细胞和自然杀伤细胞的效应功能。
Cancer Immunol Immunother. 2007 May;56(5):641-8. doi: 10.1007/s00262-006-0225-8. Epub 2006 Sep 8.
9
Metronomic therapy from a pharmacologist's view.
J Pediatr Hematol Oncol. 2006 Jun;28(6):325-7. doi: 10.1097/00043426-200606000-00001.
10
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial.阿巴西普对甲氨蝶呤抵抗的活动性类风湿关节炎患者的疗效：一项随机试验。
Ann Intern Med. 2006 Jun 20;144(12):865-76. doi: 10.7326/0003-4819-144-12-200606200-00003.
Zotero 插件